Culbertson A N & Co. Inc. decreased its holdings in shares of Zimmer Biomet Holdings Inc (NYSE:ZBH) by 5.5% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 7,109 shares of the medical equipment provider’s stock after selling 415 shares during the period. Culbertson A N & Co. Inc.’s holdings in Zimmer Biomet were worth $908,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also made changes to their positions in ZBH. BlackRock Inc. increased its position in shares of Zimmer Biomet by 1.0% during the fourth quarter. BlackRock Inc. now owns 15,965,717 shares of the medical equipment provider’s stock valued at $1,655,964,000 after acquiring an additional 153,188 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Zimmer Biomet by 1.6% during the third quarter. Vanguard Group Inc. now owns 14,511,433 shares of the medical equipment provider’s stock valued at $1,907,818,000 after acquiring an additional 228,894 shares in the last quarter. Vanguard Group Inc increased its position in shares of Zimmer Biomet by 1.6% during the third quarter. Vanguard Group Inc now owns 14,511,433 shares of the medical equipment provider’s stock valued at $1,907,818,000 after acquiring an additional 228,894 shares in the last quarter. JPMorgan Chase & Co. increased its position in shares of Zimmer Biomet by 9.8% during the third quarter. JPMorgan Chase & Co. now owns 11,595,444 shares of the medical equipment provider’s stock valued at $1,524,453,000 after acquiring an additional 1,033,717 shares in the last quarter. Finally, American Century Companies Inc. increased its position in shares of Zimmer Biomet by 23.1% during the fourth quarter. American Century Companies Inc. now owns 5,425,619 shares of the medical equipment provider’s stock valued at $562,745,000 after acquiring an additional 1,016,489 shares in the last quarter. 89.82% of the stock is owned by institutional investors and hedge funds.
Shares of Zimmer Biomet stock traded down $4.13 on Wednesday, hitting $121.39. 21,119 shares of the company’s stock were exchanged, compared to its average volume of 1,145,136. The stock has a market capitalization of $26.17 billion, a PE ratio of 15.89, a P/E/G ratio of 2.25 and a beta of 1.23. Zimmer Biomet Holdings Inc has a 1 year low of $96.99 and a 1 year high of $134.55. The company has a debt-to-equity ratio of 0.75, a current ratio of 1.83 and a quick ratio of 0.90.
Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings results on Friday, February 1st. The medical equipment provider reported $2.18 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $2.18. Zimmer Biomet had a negative net margin of 4.78% and a positive return on equity of 13.17%. The business had revenue of $2.07 billion for the quarter, compared to analysts’ expectations of $2.06 billion. During the same quarter last year, the company posted $2.10 EPS. The company’s revenue was up .1% compared to the same quarter last year. As a group, research analysts anticipate that Zimmer Biomet Holdings Inc will post 7.81 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Tuesday, April 30th. Investors of record on Friday, March 29th will be paid a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.79%. The ex-dividend date of this dividend is Thursday, March 28th. Zimmer Biomet’s dividend payout ratio (DPR) is 12.57%.
In other news, Director Betsy J. Bernard bought 4,250 shares of the stock in a transaction that occurred on Wednesday, February 6th. The shares were bought at an average price of $117.41 per share, for a total transaction of $498,992.50. Following the purchase, the director now owns 2,000 shares in the company, valued at $234,820. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Syed A. Jafry bought 1,925 shares of the stock in a transaction that occurred on Friday, March 1st. The shares were purchased at an average price of $125.52 per share, for a total transaction of $241,626.00. The disclosure for this purchase can be found here. In the last 90 days, insiders have purchased 12,860 shares of company stock worth $1,548,994. 0.72% of the stock is owned by corporate insiders.
ZBH has been the subject of a number of research analyst reports. Cantor Fitzgerald set a $135.00 target price on shares of Zimmer Biomet and gave the stock a “buy” rating in a research report on Friday, January 25th. Stifel Nicolaus cut their target price on shares of Zimmer Biomet from $150.00 to $135.00 and set a “buy” rating for the company in a research report on Tuesday, January 22nd. Citigroup raised shares of Zimmer Biomet from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $122.00 to $127.00 in a research report on Wednesday, January 2nd. SunTrust Banks lifted their target price on shares of Zimmer Biomet to $135.00 and gave the stock a “buy” rating in a research report on Tuesday, February 5th. Finally, Oppenheimer reaffirmed a “buy” rating on shares of Zimmer Biomet in a research report on Saturday, February 2nd. Four analysts have rated the stock with a sell rating, eight have assigned a hold rating and thirteen have assigned a buy rating to the stock. Zimmer Biomet currently has an average rating of “Hold” and an average target price of $129.95.
COPYRIGHT VIOLATION NOTICE: This piece was first posted by Zolmax and is the sole property of of Zolmax. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://zolmax.com/investing/culbertson-a-n-co-inc-has-908000-holdings-in-zimmer-biomet-holdings-inc-zbh/3042119.html.
Zimmer Biomet Profile
Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.
Featured Story: Asset Allocation Models, Which is Right For You?
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.